^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Lucentis (ranibizumab)

    i
    Other names: RG-3645, RG 3645, rhuFabV2, RG3645
    Associations

    News

    Trials
    Company:
    China Medical System, Novartis, Roche, Santen
    Drug class:
    VEGF-A inhibitor
    Related drugs:
    Associations

    News

    Trials
    1d
    POYANG: A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia (clinicaltrials.gov)
    P3, N=280, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
    Trial completion
    |
    Lucentis (ranibizumab)
    6d
    Pagoda: A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME (clinicaltrials.gov)
    P3, N=634, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Lucentis (ranibizumab)
    29d
    Belvedere: A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) (clinicaltrials.gov)
    P4, N=188, Recruiting, Genentech, Inc. | Trial completion date: Apr 2028 --> Oct 2027 | Trial primary completion date: Mar 2028 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    Lucentis (ranibizumab)
    1m
    Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) (clinicaltrials.gov)
    P3, N=561, Recruiting, AbbVie
    Trial initiation date • Adverse events • Real-world evidence
    |
    Lucentis (ranibizumab)
    1m
    CoRaLa II: Combination of Ranibizumab and Targeted Laser Photocoagulation (clinicaltrials.gov)
    P3, N=88, Active, not recruiting, University of Giessen | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Lucentis (ranibizumab)
    1m
    ATMOSPHERE: Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD (clinicaltrials.gov)
    P2/3, N=671, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Lucentis (ranibizumab)
    2ms
    A Study to Evaluate the Usability of the SB11 PFS in Trial Participants With Wet AMD, Macular Oedema Secondary to RVO, or mCNV (clinicaltrials.gov)
    P2, N=30, Completed, Samsung Bioepis Co., Ltd.
    New P2 trial
    |
    Lucentis (ranibizumab)
    2ms
    A Clinical Trial Evaluating the Efficacy and Safety of Sanhuang Jingshiming Pills in the Treatment of nAMD (clinicaltrials.gov)
    P3, N=450, Not yet recruiting, Tasly Pharmaceutical Group Co., Ltd | Initiation date: Jan 2026 --> Apr 2026
    Trial initiation date
    |
    Lucentis (ranibizumab)
    2ms
    Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular Edema (clinicaltrials.gov)
    P3, N=406, Recruiting, Bio-Thera Solutions
    New P3 trial
    |
    Lucentis (ranibizumab)
    2ms
    PAVILION: A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm (clinicaltrials.gov)
    P3, N=174, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
    Trial completion
    |
    Lucentis (ranibizumab)
    2ms
    Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) (clinicaltrials.gov)
    P3, N=561, Recruiting, AbbVie
    Trial initiation date • Adverse events • Real-world evidence
    |
    Lucentis (ranibizumab)
    3ms
    VOYAGER: A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products (clinicaltrials.gov)
    P=N/A, N=6000, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: Mar 2027 --> Nov 2026
    Trial primary completion date • Real-world evidence
    |
    Lucentis (ranibizumab)